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Integrated stress response is critical for gemcitabine
resistance in pancreatic ductal adenocarcinoma
LR Palam1,2, J Gore1,2, KE Craven1, JL Wilson1 and M Korc*,1
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with marked chemoresistance and a 5-year survival rate of 7%.
The integrated stress response (ISR) is a cytoprotective pathway initiated in response to exposure to various environmental
stimuli. We used pancreatic cancer cells (PCCs) that are highly resistant to gemcitabine (Gem) and an orthotopic mouse model to
investigate the role of the ISR in Gem chemoresistance. Gem induced eIF2 phosphorylation and downstream transcription factors
ATF4 and CHOP in PCCs, and these effects occurred in an eIF2α-S51 phosphorylation-dependent manner as determined using
PANC-1 cells, and wild type and S51 mutant mouse embryo fibroblasts. Blocking the ISR pathway in PCCs with the ISR inhibitor
ISRIB or siRNA-mediated depletion of ATF4 resulted in enhanced Gem-mediated apoptosis. Polyribosomal profiling revealed that
Gem caused repression of global translation and this effect was reversed by ISRIB or by expressing GADD34 to facilitate eIF2
dephosphorylation. Moreover, Gem promoted preferential mRNA translation as determined in a TK-ATF4 5′UTR-Luciferase
reporter assay, and this effect was also reversed by ISRIB. RNA-seq analysis revealed that Gem upregulated eIF2 and Nrf2
pathways, and that ISRIB significantly inhibited these pathways. Gem also induced the expression of the antiapoptotic factors
Nupr1, BEX2, and Bcl2a1, whereas ISRIB reduced their expression. In an orthotopic tumor model using PANC-1 cells, ISRIB
facilitated Gem-mediated increases in PARP cleavage, which occurred in conjunction with decreased tumor size. These findings
indicate that Gem chemoresistance is enhanced by activating multiple ISR-dependent pathways, including eIF2, Nrf2, Nupr1, BEX2,
and Bcl2A1. It is suggested that targeting the ISR pathway may be an efficient mechanism for enhancing therapeutic
responsiveness to Gem in PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is characterized by
marked chemoresistance, an overall 5-year survival rate of 7%,
and a median survival of 6–7 months.1 Gemcitabine (Gem) is
often the standard of care for patients with locally advanced or
metastatic PDAC. Gem and nab-paclitaxel combine to improve
median survival to 8.5 versus 6.7 months with Gem alone.2
The integrated stress response (ISR) is a signaling pathway
initiated upon phosphorylation of the alpha subunit of
eukaryotic initiation factor 2 (eIF2α) at serine 51 in response
to diverse stress conditions. There are four mammalian eIF2
kinases that phosphorylate eIF2α: general control non-
derepressible 2 (GCN2), which is upregulated by amino acid
starvation; protein kinase R (PKR), which is activated by viral
infections; PKR-like endoplasmic reticulum (ER) kinase
(PERK), which is upregulated by ER stress; and heme-
regulated eIF2α kinase (HRI), which is induced upon oxidative
stress or heme deprivation.3–6 Phosphorylated eIF2α
(p-eIF2α) markedly attenuates translation initiation and overall
protein synthesis, allowing for conservation of cellular
resources. Moreover, p-eIF2α facilitates the preferential
translation of certain mRNAs, most notably ATF4, whose
upregulation promotes the expression of genes involved in
oxidative stress (OS), metabolism, and nutrient uptake.7–9
Thus, gene reprograming by p-eIF2α allows cells to recover
from stress-induced damage facilitating survival in response
to mild stress and promoting apoptosis in response to chronic
stress.9,10
PDAC is associated with constitutive activation of several
pro-survival pathways including AKT, NFkB, and STAT3.11,12
PDACs also harbor major driver mutations, including Kras
(~95%) and p53 (~75%), which may also contribute to
apoptosis resistance.13,14 Pancreatic cancer cells (PCCs)
also exhibit enhanced autophagy, and their chemoresistance
may be enhanced by autophagy.15,16 However, suppressing
autophagy for therapeutic purposes may be associated with
enhanced tumor growth and chemoresistance.17
The ISR pathway is activated in response to various cellular
stresses such as hypoxia and nutrient deprivation,18,19
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conditions that exist within the PDAC microenvironment.
Accordingly, in the present study, we conducted in vitro and
in vivo studies and RNA-seq analysis to explore the possibility
that Gem activates an antiapoptotic response in PCCs via the
ISR pathway. We now report that ISRIB enhances Gem
chemosensitivity in PCCs by suppressing ISR and its down-
stream antiapoptotic pathways.
Results
Gemcitabine activates the integrated stress response
pathway in pancreatic cancer cells. Gem induces oxida-
tive stress in PCCs,20,21 and oxidative stress can activate ISR
pathways.8 It is not known, however, whether Gem’s actions
in PCCs are modulated by ISR signals. We therefore studied
the effects of ISRIB, a novel ISR inhibitor,22 on Gem-activated
stress pathways. In ASPC-1 and PANC-1 human PCCs, eIF2
phosphorylation was decreased at 6, 12, and 24 h following
ISRIB addition (Figure 1a). By contrast, Gem increased
p-eIF2 and ATF4 protein levels at the same time points
(Figure 1a), whereas ISRIB attenuated these Gem-induced
effects (Figure 1a), indicating that ISRIB attenuates p-eIF2
and downstream events in PCCs. Given that GADD34
delivers protein phosphatase-1 (PP1) to the vicinity of eIF2
and facilitates PP1-mediated p-eIF2 dephosphorylation,23 it
was of interest to determine whether eIF2 dephosphorylation
was similarly modulated by GADD34 in PCCs. Indeed, when
PANC-1 cells were transfected with a GADD34 cDNA, there
was a marked reduction in eIF2 phosphorylation which was
associated with marked decreases in ATF4 protein levels
(Figure 1b).
We next sought to assess the effects of Gem and ISRIB on
additional stress pathway modulators. By comparison to
control PANC-1 cells, Gem induced 4-fold and 10-fold
increases in ATF4 and ATF3 mRNA levels, and 8-fold and
6-fold increases in CHOP and GADD34 mRNA levels,
respectively (Figure 1d). Gem also increased the levels of all
four proteins (Figure 1c). Although ISRIB slightly decreased
basal ATF4 and ATF3 mRNA and protein levels, it did not alter
CHOP or GADD34 mRNA levels in PANC-1 cells, but it
significantly attenuated Gem’s ability to upregulate these
mRNAs and proteins (Figure 1c).
ISRIB suppresses signaling downstream of p-eIF2 but is not
known to alter either basal or stress-induced eIF2
phosphorylation.22 In view of ISRIB’s ability to decrease both
basal and Gem-induced p-eIF2 in PCCs (Figure 1a), we
sought to determine whether ISRIB also modulates eIF2
dephosphorylation in mouse embryo fibroblasts (MEFs).
ISRIB did not alter basal or Gem-induced eIF2 phospho-
rylation in MEFs (Figure 1e), but markedly attenuated
Gem-induced increases in ATF4 protein levels (Figure 1e).
Thapsigargin (0.1 μM), an ER stress-inducer, caused a robust
increase in ATF4 levels compared with Gem, suggesting that
Gem-induced stress is relatively mild with respect to the ISR
pathway. To confirm that p-eIF2modulates ATF4 expression in
MEFs, we examined Gem actions in MEFs that express wild-
type eIF2α (MEF-S/S) or a mutated eIF2α in which serine 51
was mutated to alanine (MEF-A/A). Gem readily induced
eIF2 phosphorylation and upregulated ATF4 protein levels in
MEF-S/S cells, but not in MEF-A/A cells, confirming that
Gem-mediated upregulation of ATF4 is dependent on
phospho-eIF2 (Figure 1f).
ISRIB enhances the inhibitory actions of gemcitabine on
pancreatic cancer cell survival. To determine whether
inhibition of ISR pathways in PCCs modulates their survival,
cells were incubated for 72 h with 10 nM to 5 μM ISRIB. The
effective concentration of ISRIB required for inhibition of
AsPC-1 and PANC-1 cell survival was 250 nM (Figures 2a
and c). Next, both cell lines were incubated for 72 h with
0.01 μM to 100 μM Gem, in the absence or presence of
250 nM ISRIB for 72 h. Both AsPC-1 and PANC-1 cells were
relatively resistant to Gem’s inhibitory actions, exhibiting
IC-50 values of 50 and 15 μM, respectively (Figures 2b and d).
In combination with 250 nM ISRIB, the half-maximal inhibitory
concentration of Gem in both cell lines decreased to 100 nM
(Figures 2b and d). Moreover, in the presence of ISRIB,
Gem’s maximally effective growth inhibitory concentration
was 10 and 0.5 μM in ASPC-1 and PANC-1 cells, respectively
(Figures 2b and d). To assess whether the decrease in cell
survival was due to enhanced apoptosis, cleaved caspase-3
levels and caspase activity were examined (Figures 2e–h).
Although ISRIB alone did not induce caspase-3 cleavage or
caspase-3/7 activity in either cell line, it increased Gem’s
effects on cleaved caspase-3 levels and significantly
enhanced caspase activity in both cell lines when compared
to Gem alone (Figures 2e–h).
Gemcitabine represses global mRNA translation while
preferentially enhancing ATF4 translation. Stress-induced
eIF2 phosphorylation enhances ATF4 and CHOP expression
at the mRNA and protein levels, but reduces global protein
synthesis, thereby conserving cellular energy.3,24 ISRIB
markedly reduced Gem-induced ATF4 protein levels, but only
slightly decreased Gem-induced ATF4 mRNA upregulation
(Figure 1). Given the inability of ATF4 mRNA to be translated
into protein in the presence of ISRIB, it is likely that ISRIB
reprograms this pathway at a translational level. To assess this
possibility, polyribosomal profiling was performed, revealing
that Gem did not alter the sedimentation profiles of 40/43S and
60S ribosomal subunits, but increased the monosome 80S
peak, pointing to a Gem-induced translation initiation defect
(Figure 3a). Moreover, Gem markedly decreased the number
of polyribosome-associated mRNAs when compared with
control cells, whereas ISRIB completely reversed these
Gem-induced alterations (Figure 3a). Thus, Gem suppresses
global protein synthesis and ISRIB reverses this block.
GADD34 is upregulated by Gem and this effect is partially
reversed by ISRIB (Figure 1c). Therefore, we sought to assess
the consequences of transient overexpression of GADD34 on
Gem-induced changes in polyribosomal sedimentation.
GADD34 expression did not alter the sedimentation profile
of PANC-1 cells and did not affect Gem-induced increases in
the monosome 80S peak (Figure 3b). By contrast, GADD34
mimicked the effect of ISRIB and reversed the Gem-induced
decrease in mRNA-associated polyribosomes (Figure 3b).
Thus, GADD34 attenuated translation repression in response
to Gem, confirming that eIF2 phosphorylation is essential for
this Gem-induced action. Similar results were observed with
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Figure 1 Gemcitabine induces the integrated stress pathway in pancreatic cancer cells. (a) AsPC-1 and PANC-1 cells were incubated with 0.5 μM ISRIB or 10 μM Gem for
indicated times and protein lysates were analyzed by immunoblotting for phospho-eIF2, total eIF2, and ATF4 using specific antibodies. ERK2 served as loading control. (b) Empty
vector or GADD34 expression plasmid DNA was transfected into PANC-1 cells, which were incubated 24 h later with 10 μM Gem. Protein lysates were analyzed by
immunoblotting. (c) PANC-1 cells were incubated for 36 h with 0.5 μM ISRIB or 10 μM Gem and protein lysates were analyzed by immunoblotting for ATF4, ATF3, GADD34, and
CHOP using specific antibodies. ERK2 served as loading control. (d) PANC-1 cells were incubated with 0.5 μM ISRIB or 10 μM Gem for 24 h. ATF4, CHOP, ATF3, and GADD34
mRNA levels were measured using qRT-PCR. Relative actin mRNA levels were used for normalization. Data are the means± S.D. from three experiments. *Po0.05, **Po0.001
compared with control, ##Po0.01 compared with ISRIB, and $Po0.05 compared with Gem+ISRIB. (e) MEFs were incubated for 6 h with 10 μM Gem in the absence and
presence of ISRIB. As a positive control, MEFs were also incubated for 6 h with thapsigargin (0.1 μM). (f) Wild-type MEFs or MEFs mutated for eIF2α at serine 51 (to alanine)
were incubated with 10 μM Gem for indicated time point and analyzed by immnuoblotting. Panels (a, b, d and e) show representative data from three independent experiments
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Gem in wild-type MEFs but not in mutated MEFs (MEF-A/A)
(Supplementary Figure S1). ATF4 preferentially associates
with polyribosomes during stress-induced eIF2 phospho-
rylation.25 To confirm this, we measured ATF4 mRNA
distribution across polyribosome fractions using sucrose
density centrifugation. By comparison to control, polysome-
associated ATF4 transcript levels were enhanced by 22% in
Gem-treated PANC-1 cells, but this increase did not occur
when ISRIB was combined with Gem (Figure 3c). Further-
more, Gem enhanced the readout of a TK-ATF4 5′UTR-
Luciferase reporter assay,25 and this effect was completely
reversed by ISRIB (Figure 3d), confirming that Gem-induced
stress also acted to promote preferential translation
of mRNAs.
Figure 2 Suppression of integrated stress pathway enhances gemcitabine chemosensitivity. (a) AsPC-1 cells were incubated with ISRIB alone or (b) Gem alone, or ISRIB
and Gem for 72 h as indicated, and MTTassays were performed. Data are the means±S.D. from three experiments. *Po0.001 compared with control, **Po0.005 compared
with Gem alone, #Po0.005 compared with Gem (1 μM)+ISRIB (250 nM). (c) PANC-1 cells were incubated with ISRIB alone or (d) with Gem alone or with Gem+ISRIB for 72 h as
indicated, and MTT assays were performed. Data are the means±S.D. from three experiments. *Po0.001 compared with control, **Po0.005 compared with Gem alone,
$Po0.005 compared with 0.1 μM Gem+250 nM ISRIB. (e and g) AsPC-1 cells were incubated with 0.5 μM ISRIB alone or in combination with 10 μM Gem. (f and h) PANC-1
cells were incubated with 0.5 μM ISRIB alone or in combination with 1 μM Gem. Cell lysates were immunoblotted for cleaved caspase-3 protein in (e and f) and caspase-3/7
activity was measured in (g and h). Data shown are from three independent experiments in (e and f). Data are the means± S.D. from three experiments in ( g and h). ##Po0.01
compared with control and ISRIB, ***Po0.01 compared with control, ISRIB, and Gem
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Gemcitabine and ISRIB interact to modulate multiple
signaling cascades. To assess the actions of Gem and
ISRIB on gene expression, RNA-Seq data from PANC-1 cells
incubated with Gem and/or ISRIB were analyzed next. Gem
and ISRIB altered the expression of 1993 and 29 genes
(41.5-fold increase or o− 1.5-fold decrease, Po0.001),
respectively, compared with control (Figure 4a). Out of 1993
genes altered by Gem, 690 were downregulated and 1303
were upregulated, and from the ISRIB-responsive genes, 27
were downregulated and 2 were upregulated. By contrast, the
Figure 3 Gemcitabine causes translation repression in pancreatic cancer cells. (a) PANC-1 cells were incubated for 12 h in the absence or presence of 10 μMGem or 0.5 μM
ISRIB. Cell lysates were subjected to sucrose gradient centrifugation, and gradients were fractionated in-line with 254 nm UVabsorbance measurement. Top fractions containing
free ribosomal subunits are labeled as 40/43S, 60S. Mono ribosomes are labeled as 80S. Ribosomes bound to RNA fractions were labeled as polysomes. (b) PANC-1 cells were
transfected with an empty vector or the GADD34 plasmid DNA, and incubated 24 h later with 10 μM Gem for 12 h. Cell lysates were analyzed for polysome profiles as in (a).
(c) PANC-1 cells were incubated in the absence or presence of Gem or ISRIB+Gem and subjected to sucrose gradient centrifugation as in (a). Fractions were collected and
luciferase (10 ng/ml) spiked into each fraction. RNA Isolated and ATF4 transcript levels were quantitated using qRT-PCR, and normalized to spike-in luciferase control. The
percent total ATF4 transcript for each fraction is represented. Fractions 5, 6, and 7 corresponds to fractions with polysomes rich in translation. (d) PANC-1 cells were transfected
with the TK-ATF4-Luc plasmid construct that with illustrated features: ATF4 5′UTR harboring uORF1 and uORF2, TK promoter and Luciferase coding region. At 24 h post
transfection cells were incubated for 12 h in the absence or presence of 10 μM Gem and 0.5 μM ISRIB. Firefly luciferase units were measured and normalized to internal control
Renilla luciferase activity. Data are the means±S.D. of three experiments. *Po0.05, **Po0.005 compared with control, ##Po0.001 compared with Gem+ISRIB. Panels a and b
show representative data from three independent experiments
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combination of Gem and ISRIB altered the expression of
2232 genes (1425 genes up, 807 genes down, Po0.001),
and 620 of these genes (~28%) were modulated by the
combination of Gem and ISRIB (Figure 4a). Genes
modulated downstream of eIF2 signaling were identified from
a previous study that used a genetically engineered artificial
eIF2 kinase in MEFs that express wild type or mutated
eIF2α.9 Expression analysis following Gem-induced ISR
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revealed that 225 ISR-associated genes9 were significantly
modulated (Po0.001; Figure 4b, Supplementary Table 1).
This list included such genes as ATF3, CHOP (DDIT3),
GADD34 (PPP1R15A), GADD45a, SLC3A2, TXNIP, and
SLC1A4 (Figures 4b and c), and ISRIB antagonized these
Gem-induced changes (Figure 4b). Using quantitative
RT-PCR (qRT-PCR) we validated the RNA-seq data by
measuring multiple transcripts downstream of p-eIF2,
including ATF3, CHOP, GADD34, and other well-known
ATF4-regulated genes such as ASNS, TRIB3, GAS-5,
SLC7A11, SESN2, STC2, and SAT1. qRT-PCR confirmed
that Gem enhanced the levels of all of these mRNAs,
and that ISRIB attenuated these effects (Supplementary
Figure S4a). Moreover, Gene Set Enrichment Analysis
(GSEA) of p-eIF2-dependent genes9 within our RNA-Seq
data set from ISRIB, Gem, and Gem+ISRIB treated cells
revealed negative (NES: − 3.63, P-value o0.001), positive
(NES: 2.88, P-value o0.001), and negative (NES: − 2.14,
P-value o0.005) enrichment of eIF2 signaling, respectively,
suggesting that ISRIB can attenuate Gem-induced eIF2
signaling (Supplementary Figure S4b).
Ingenuity Pathway Analysis (IPA) confirmed that multiple
pathways were modulated by Gem, and that ISRIB enhanced
Gem-mediated expression of genes implicated in BRCA1’s
DNA damage response and hereditary breast cancer signaling
(Figure 4d). However, ISRIBmarkedly attenuatedGem’s effects
on the expression of genes involved in eIF2 signaling, NRF2-
mediated oxidative stress responses, and protein kinase
A pathways (Figure 4d). The most dramatic inhibitory changes
occurredwith genes involved in eIF2 signaling (Figures 4d and e,
Supplementary Table 2). Thus, ISRIB suppressed Gem-
induced expression of ribosome-related genes such as 60S
ribosomal protein L10 (RPL10) and ~12 related RPL
members, 40S ribosomal protein S11 (RPS11) and four
related RPS members, as well as the expression of genes
implicated in signaling,26 such as those encoding phosphati-
dylinositol-4,5-bis-phosphate-3-kinase, catalytic subunit beta
(PK3CB), and serine/threonine-protein phosphatase PP1-
alpha catalytic subunit (PPP1CA). Some genes were upregu-
lated by Gem and Gem+ISRIB, but were not previously known
to be ISR related. These include inhibin A which may
contribute to cancer-associated cachexia,27 nitric oxide
synthase-2 (NOS2) which may enhance resistance to
apoptosis,28 CCNE which encodes cyclin E1, and Nedd4-
binding protein 2-like 1 (N4BP2L1) which is a Bcl3-binding
protein (Figure 4f) whose upregulation may lead to increased
sensitivity to platinum.29,30
Gemcitabine induces antiapoptotic Nupr1 and pro-
survival factors via the ISR pathway. Nuclear protein 1
(Nupr1), also known as p8, is a helix–loop–helix protein that
is overexpressed in PDAC and that enhances pancreatic
tumorigenesis by suppressing oncogenic K-ras-induced
senescence and inhibiting apoptosis.31 Nupr1 also promotes
Gem chemoresistance in PCCs by inhibiting stress-induced
cell apoptosis,32,33 whereas ATF4/CHOP signaling induces
Nupr1 expression in response to amino acid deprivation.34
Our RNA-seq data revealed that ISRIB suppressed both
basal and Gem-stimulated Nupr1 mRNA levels, and qRT-
PCR and immunoblotting confirmed these results (Figures 5a
and f). IPA of RNA-seq data confirmed that Gem induced
alterations in the expression of Nupr1 network genes and that
ISRIB blocked this effect (Figure 5b, Supplementary Table 4).
We therefore sought to determine whether Nupr1 contributes
to the ISR’s role in Gem chemoresistance, by first assessing
whether Nupr1 expression is modulated by PERK or ATF4.
PERK knockdown, which reduced Gem-induced CHOP
upregulation (Supplementary Figure S2), and ATF4 knock-
down both suppressed basal and Gem-stimulated Nupr1
levels (Figure 5c). Moreover, ATF4 or Nupr1 knockdown both
enhanced Gem-stimulated caspase-3/7 activity (Figure 5d).
Together, these findings demonstrate that Nupr1 enhances
chemoresistance downstream of the ISR.
Gem also enhanced the expression of the antiapoptotic
factors brain expressed X-linked 2 (BEX2) and Bcl-2 related
protein A1 (BCL2A1), which was completely blocked by
ISRIB (Figures 5e–g), and markedly suppressed by ATF4
knockdown (Figures 5h and i). Thus, the ISR upregulates
these genes, in part, through ATF4. In addition, Gem
increased the expression of genes involved in reactive
oxygen species (ROS) reduction, such as cystathionine
gamma lyase (CTH), solute carrier family 7 member 11 or
xCT (SLC7A11), and sestrin2 (SESN2), and genes related to
glucose deprivation and nutrient stress such as phosphoenol
carboxykinase2 (PCK2), branched chain amino acid transa-
minase 1 (BCAT1), phosphoglycerate dehydrogenase
(PHGDH), and phosphoserine aminotransferase 1 (PSAT1)
(Supplementary Figure S3). qRT-PCR validated the RNA-
seq data, confirming that ISRIB completely blocked upregu-
lation of these transcripts (Supplementary Figure S4). Thus,
by upregulating ATF4, Gem activates apoptosis resistance,
and oxidative and nutrient stress response pathways that are
attenuated by ISRIB.
Inhibition of gemcitabine induced ISR pathway attenu-
ates tumor growth in vivo. We next examined PANC-1 cell-
derived tumor growth in an orthotopic nude mouse model. All
the animals had approximately the same tumor size prior to
treatment initiation (Figure 6a). ISRIB alone or Gem alone did
not significantly reduce tumor volumes by comparison with
Figure 4 Genome-wide analysis for response to gemcitabine and ISRIB. PNAC-1 cells were incubated for 36 h in the absence or presence of 10 μMGem 0.5 μM ISRIB, and
collected RNA was used for RNA transcriptome sequencing. (a) Total number of genes with significant change in gene expression (41.5-folds increase or o− 1.5-fold
decrease, Po0.001) following indicated incubations compared with control are represented in a Venn diagram. (b) Heat map for fold changes in gene expression (Po0.001)
over control following indicated incubations is shown for genes involved in the ISR pathway. ISR genes and gene expression data from RNA-seq analysis are shown. (c) ISR
genes with more than 2-fold change in gene expression (Po0.001) in response to Gem compared with control are shown. (d) IPA was performed on obtained RNA-seq data and
major canonical signaling pathways that were modulated in response to drugs are represented. (e) Heat map for fold changes in gene expression (Po0.001) over control
condition following indicated incubations is shown for genes involved in eIF2 signaling. Network of genes involved in eIF2 signaling was collected from IPA as described in
Materials and Methods. (f) Top 20 genes that are differentially regulated in response to Gem alone versus Gem+ISIRB are shown (Po0.001)
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the control group (Figure 6a). By contrast, concomitant
treatment with Gem and ISRIB significantly reduced tumor
volumes after 8 weeks, when compared with control, Gem, or
ISRIB treatment groups (Figures 6a and b). Although Gem,
ISRIB, or their combination did not alter tumor (Figure 6c) or
adjacent normal pancreas histology (Supplementary Figure S5),
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there was a marked increase in the number cells that were
positive for cleaved PARP in mice treated with Gem and
ISRIB, when compared with control, Gem, or ISRIB treated
groups (Figures 6c and d). By contrast, the number of
phospho-histone H3-positive cells was similar in all four
groups (Supplementary Figure S5). Thus, combined Gem
and ISRIB therapy enhances apoptosis in vivo without
altering proliferation.
Discussion
Cancers exhibit self-sufficiency, unlimited cell growth,
sustained ability to obtain nutrients, apoptosis resistance,
capacity to invade andmetastasize, and insensitivity to growth
inhibitory pathways.35 In PDAC, these aberrant processes are
associated with multiple and diverse genetic alterations
impacting ~12major signaling pathways.36–38 Despite numer-
ous clinical trials, current therapies for metastatic PDAC are
having limited success. Thus,Gemprolongs life by 6–8weeks,
while the addition of erlotinib or nab-paclitaxel adds 12 days or
15 weeks, respectively, to overall survival.39 In addition, the
combination of 5-fluorouracil (5-FU), leucovorin, irinotecan,
and oxaliplatin (FOLFIRINOX), which is generally restricted to
patients with excellent performance status, increases survival
by 18 weeks.40 Although patients with a BRCA mutation
signature may respond to either platinum drugs or PARP
inhibitors,38 there are no curative therapies in PDAC, under-
scoring the urgent need for innovative therapeutic strategies.
The etiology for therapeutic failure in PDAC is multifactorial.
The abundance of gene mutations and overexpression of
receptors and ligands results in the activation of aberrant
signaling pathways that enhance the resistance of PCCs to
chemotherapeutic agents,35–38 whereas the desmoplastic and
hypoxic tumor microenvironment impedes efficient drug
delivery into the pancreatic tumor mass.41,42 In the case of
Gem, resistance may be due to various mechanisms, such as
decreased expression of equilibrative nucleoside transporter-
1 (hENT1), decreased deoxycytidine kinase (dCK) activity
which translates into attenuated dCK activation of Gem, and
increased ribonucleotide reductase (RR) expression which
leads tomore efficient DNA repair due to increased generation
of deoxyribonucleoside triphosphates.13,43 Moreover, Gem-
induced upregulation of DUSP1 results in activation of a
negative feedback loop that promotes chemoresistance,44
upregulation of HMGA1 enhances pro-survival signals
through an Akt-dependent mechanism,45 and increased
expression of multidrug resistance (MDR) genes including
ABCC1, ABCC3, ABCC5, and ABCB1 promotes drug efflux.46
MUC4 promotes PDAC growth andmetastasis, and negatively
regulates equilibrative/concentrative nucleoside transporter
(hCNT1) levels in PCCs via NF-κB, thereby conferring Gem
resistance.47 MUC4 also attenuates mitochondrial cyto-
chrome c release and caspase-9 activation by inactivating
the pro-apoptotic protein Bad.48 Gem also induces ROSwhich
upregulate CXCR4 levels in PCCs via mechanisms involving
activation of NF-κB.49
In the current study we uncovered a novel mechanism
whereby Gem activated a cytoprotective ISR pathway in PCCs
by inducing eIF2 phosphorylation and downstream ISR targets.
We also demonstrated that blocking ISR pathway activation
with the symmetric bisglycolamide ISRIB greatly enhanced
Gem sensitivity by promotingPCCapoptosis in vitro and in vivo.
Moreover RNA-seq data on ISRIB-treated PANC-1 cells
showed reduced levels of genes involved in amino acid and
glucose metabolism such as PHGDH, PCK2, aldehyde
dehydrogenase 1 family member2 (ALDH1L2), asparagine
synthase (ASNS), PSAT1, and SLC1A4 (a glutamate/neutral
amino acid transporter) (Supplementary Table 5). ISIRB also
inhibited expression of genes that regulate protein synthesis
such as ribosomal protein S6 kinase A2 (RPS6A2)
(Supplementary Figure S3). It is therefore possible that down-
regulation of these key genes contributes to ISRIB-mediated
inhibition of PCC proliferation in vitro.
ISRIB also reversed Gem-induced translation repression,
but the molecular mechanism underlying this effect is not
known. Nonetheless, recent reports suggest that ISRIB action
intervenes at the level of eIF2-phosphorylation-mediated
stress granule formation, thereby reversing stress-induced
translation repression.50 Moreover, stress granule formation
transiently protects cytosolic RNAs from harmful effects during
cell stress.51 Therefore, it is possible that the observed
translation repression in PCCs may be due to Gem-induced
p-eIF2mediated stress granule formation. ISIRB also pro-
motes eIF2 guanine nucleotide exchange factor (eIF2GEF)
activity towards eIF2, thereby inhibiting the ISR pathway.52 It is
therefore possible that ISRIB may also act in a similar manner
Figure 5 Inhibition of ISR pathway completely reduces gemcitabine-induced Nupr1 increase in PANC-1 cells. (a) Nupr1 expression data from RNA-seq analysis and qRT-PCR is
represented. **Po0.001 compared with control, ##Po0.001 compared with ISRIB, $Po0.001 compared with Gem+ISRIB. PANC-1 cells were incubated with 0.5 μM ISRIB, 10 μM
Gem, or ISRIB+Gem for 36 h, and RNA was analyzed for Nupr1 mRNA levels using qRT-PCR. Data are the means ±S.D. of three experiments. **Po0.001 compared with control,
##Po0.001 compared with ISRIB, $Po0.001 compared with Gem+ISRIB. (b) Heat map for fold changes in gene expression in response to indicated drugs over control for genes
involved in Nupr1 network, based on Nupr1 network genes collected from Ingenuity Pathway Analysis as described in Materials and Methods. (c) PANC-1 cells stably expressing
either control-shRNA or PERK-shRNA and PANC-1 cells with ATF4 siRNAwere incubated with 10 μMGem for 24 h, and RNAwas analyzed for Nupr1 mRNA expression levels. Data
are the means ±S.D. of three experiments. **Po0.001 compared with control-shRNA and PERK-shRNA, ##Po0.001 compared with PERK-shRNA, *Po0.001 compared with
control-shRNA, $Po0.001 compared with PERK-shRNA in the presence of Gem. (d) PANC-1 cells were transfected with indicated siRNA, and incubated 48 h later in the absence or
presence of 10 μM Gem for 24 h. Caspase-3 activity was measured using Casp3/7 glow assay. Data are the means ±S.D. from three independent experiments. **Po0.001
compared with control, ##Po0.001 compared with sham-siRNA control and sham-siRNA with Gem, ***Po0.001 compared with sham-siRNA control, ATF4 siRNA control, and
sham-siRNA with Gem, $Po0.001 compared with sham-siRNA control, Nupr1-siRNA control, and sham-siRNA with Gem. (e) Antiapoptotic factor BEX2 and (g) BCL2A1 expression
data from RNA-seq analysis and qRT-PCR analysis are shown; **Po0.001 compared with control and ISRIB, ##Po0.001 compared with Gem, $Po0.001 compared with Gem
+ISRIB. (f) PANC-1 cells were incubated with 0.5 μM ISRIB or 10 μMGem for 36 h and protein lysates were analyzed by immunoblotting for Nupr1 and BEX2 using specific antibody.
ERK2 served as loading control. Nupr1 protein levels were quantified from the blots and fold changes in expression are shown. Data are the means±S.D. of three experiments.
*Po0.01 compared with control, ISRIB, and Gem+ISRIB. (h and i) PANC-1 cells expressing ATF4 siRNA were incubated with 10 μM Gem for 24 h, and RNA was analyzed for (h)
BEX2 mRNA and (i) BCL2A1 expression levels. Data are the means ±S.D. of three experiments. **Po0.001 compared with control siRNA and ATF4 siRNA, ##Po0.001 compared
with ATF4 siRNA, *Po0.001 compared with control siRNA, $Po0.001 compared with ATF4 in the presence of Gem
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in PCCs. While further studies are necessary to explore these
possibilities, ISRIB alone modulated the expression of 29
genes (Po0.001), but when combined with Gem, ISRIB
altered expression of a much larger set of genes (Figure 4a),
including genes not previously reported to be associated with
ISR pathways (Figure 4f, Supplementary Table 3). Thus,
ISRIB interferes with PCC adaptation to stress.
The chromatin factor Nupr1 is essential for survival of PCCs
exposed to stress, and high Nupr1 levels are associated with
poor prognosis in PDAC.32,33 Moreover, Nupr1 deficiency
sensitizes PCCs to Gem and to other novel nucleoside
analogs, such as Ly101-4b andWJQ63.32 In the present study
we decreased Nupr1 levels by targeted siRNA, or by inhibiting
the ISR pathway with ISRIB or ATF4-targeting siRNA; each
approach sensitized PCCs to Gem. These observations are
concordant with earlier studies using MEFs and NIH3T3 cells,
which showed that nutrient deprivation triggers Nupr1
expression via ATF4/CHOP, and that the Nupr1 promoter
has the CHOP binding site ATTGCATCA.34 Moreover, our
RNA-seq data and qRT-PCR validation demonstrated that
Figure 6 Inhibition of gemcitabine induced ISR pathway decreases PANC-1 orthotopic tumor growth. (a) PCCs were injected into the pancreas of athymic mice as described
in Materials and Methods. High-resolution ultrasound images were obtained at 2 weeks post-PCC injection, and at indicated treatment times. Tumors are outlined and are
representative images from six mice per group. (b) Tumor volumeswere calculated using 3-D abdominal imaging. There was a step-wise decrease in tumor volumes from Vehicle-
treated, to ISRIB-treated, to Gem-treated, and to Gem+ISRIB-treated mice. Data are the means± S.D.; ***Po0.05 compared with control, ##Po0.05 compared with ISRIB.
(c) H&E and PARP staining was performed on paraffin-embedded tissue sections (0.5 μm thick), bars= 50 μm. (d) PARP-positive cells were counted and tabulated after
normalization to percent of control. Data are the means± S.D. for four experiments. ***Po0.001, ##Po0.001, $Po0.001 compared with control, ISRIB, and Gem+ISRIB
treatments, respectively
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Gem increases Nupr1 levels via the ISR pathway. Taken
together with our PERK and ATF4 knockdown studies, these
findings suggest that the PERK4eIF2-P4ATF44CHOP
pathway is involved in Nupr1 transcriptional regulation
in PCCs.
In addition to enhancing cell survival through the above
mechanisms, Gem upregulated the antiapoptotic proteins
BEX2 and Bcl2A1, and these actions were suppressed by
ISRIB or ATF4 knockdown. BEX2 inhibits mitochondrial
apoptosis in breast tumors and plays a role in G1 cell cycle
progression.53,54 BEX2 also upregulates the pro-survival
factor Bcl-2 and downregulates pro-apoptotic factors BAD,
BAK1, and PUMA.53 Similarly, Bcl2A1 is an antiapoptotic
protein that is highly expressed in many cancers.55 It has been
implicated in tumorigenesis and chemoresistance,55 as well
as resistance to the Bcl-2/Bcl-Xl inhibitor ABT-737.56 In the
present study, ISRIB was well-tolerated in an orthotopic tumor
model. There was increased PARP cleavage in the tumors
without decreased proliferation in response to combined
Gem/ISRIB treatment compared to either drug alone, sug-
gesting that reduced tumor growth was due to enhanced
apoptosis. Previous studies have demonstrated that the
PERK specific inhibitor GSK2656157 reduces cancer cell
growth in vivo by impairing angiogenesis and reducing amino
acid metabolism.57 However, administration of GSK2656157
to mice for 2 weeks caused pancreatic degeneration and other
long-term toxicities.57,58 By contrast, ISIRB is well-tolerated
and restores protein synthesis without causing pancreas
toxicity.59 Our study is in agreement with these observations
since ISRIB did not impact the normal pancreatic parenchyma
adjacent to the orthotopic tumors. Taken together, our findings
indicate that Gem-induced ISR pathway activation promotes
chemoresistance by upregulating multiple antiapoptotic fac-
tors such as Nupr1, Bcl2A1, BEX2, and NRF2, and that ISR
pathway inhibition with ISRIB or similar molecules could be a
novel mechanism for enhancing Gem chemosensitivity in
PDAC, and could greatly increase the therapeutic effective-
ness of Gem-based combinatorial therapies.
Materials and Methods
Ethics statement. All animal experiments conducted at Indiana University
were approved by the Institutional Animal Care and Use Committee of Indiana
University.
Cell culture. AsPC-1 and PANC-1 human PCCs were obtained from the
American Type Culture Collection (Manassas, VA, USA). Mouse embryo fibroblasts
(MEFs) were a kind gift from Dr. Ronald Wek (IU School of Medicine, Indianapolis,
IN, USA).60 PANC-1 and MEF cells were cultured in DMEM, and AsPC-1 cells were
cultured in RPMI 1640. Media were supplemented with 5% (PCCs) or 10% (MEFs)
FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. Cells were incubated at
37 °C in a humidified 5% CO2 incubator.
Transfection and transduction. PANC-1 cells were GFP labeled using a
lentiviral vector GFP plasmid DNA (Open Biosystems, Pittsburgh, PA, USA). shRNA
expression plasmids (TRCN0000262379; Sigma, St Louis, MO, USA) were used to
silence PERK eIF2 kinase by lentiviral transduction.61 The GADD34 DNA fragment
which was amplified from PANC-1-derived cDNA was inserted into pcDNA4 at Not1
and XHO1 sites. An N-terminal flag tag was added using phospho primers, and the
start codon context in GADD34 coding sequence was changed to a strong Kozak
context (GCCACCAUGG) to achieve high GADD34 expression after sequence
confirmation (Sangers method; IU DNA sequencing core). siRNA specific for ATF4
(SR300328c), non-targeting control siRNA (Origene, Rockville, MD, USA), or siRNA
specific for Nupr1 (SI02664333; Qiagen, Valencia, CA, USA) was transfected
(20 nM each) into PANC-1 cells at 70% confluence using lipofectamine-2000 (Life
technologies, Grans Island, NY, USA).
Immunoblotting. Immunoblotting was performed62 using antibodies against:
ATF4 (11815), phospho-eIF2 (3398), total eIF2 (9722), and Casp3 (9661) all from
Cell Signaling Technology (Danvers, MA, USA); Flag-M2 (F1804) from Sigma-
Aldrich (St Louis, MO, USA); Nupr1 (ab6028) from Abcam (Cambridge, MA, USA);
Bex2 (sc48966), ATF3 (sc188), GADD34 (sc825), CHOP (sc7351), and ERK2
(sc154) were all from Santa Cruz Biotechnology (Dallas, TX, USA).
Statistical analysis. SigmaPlot (Systat Software Inc., San Jose, CA, USA)
was used for one-way ANOVA. P-values are shown in Figures 5e, 6b and d,
Supplementary Figure S4. Student’s t-test was used for data in Figures 1c, 3, 5b
and c, Supplementary Figure S2. For RNA-seq data, the DESeq algorithm63 were
used, providing P-values for differential gene expression as shown in respective
figures. We used six mice per group for in vivo studies based on a calculation of
80% power to detect any tumor size difference greater than 18% with a 5% type I
error rate, based on tumor size variability (9.8%) in PANC1 tumors.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) and Casp3/7 glow assays. MTT assays were performed as
described.62 Caspase cleavage was measured using the caspase-3/7 glow assay
(Promega, Madison, WI, USA).
Luciferase reporter assay. TK-ATF4-5′UTR-Luc plasmid was a kind gift
from Dr. Ronald Wek. TK-ATF4-Luc was transfected into PANC-1 cells (80%
confluent) using Lipofectamine-2000. Lysates were assayed for luciferase activity
using Dual-Luciferase assay system (Promega) and a Synergy H1 hybrid reader
(Biotek, Winooski, VT, USA).
RNA preparation and transcriptome data analysis (RNA-
seq). PANC-1 cells were incubated for 36 h in the absence or presence of
10 μM Gem and/or 0.5 μM ISRIB. RNA was collected using Trizol (Catalog # 15596-
018, Invitrogen, Grand Island, NY, USA), treated with DNAse using DNase Kit
(Catalog # AM1907, Ambion, Grand Island, NY, USA) and re-purified using RNeasy
kit (Catalog # 74106, Qiagen). Total RNA (5 μg) was used for transcriptome
analysis. Read count quantification of triplicate RNA samples from each treatment
condition was performed using the Illumina HiSeq 2000 platform (BGI-Americas,
Cambridge, MA, USA). Differential expression analysis was performed using the
DESeq algorithm.63 ISR pathway network gene information (Figure 4b) was
obtained as follows: 654 probe sets from the mouse Affymetrix U74Av2 chip
respective to eIF2-phosphorylation-dependent genes were downloaded,9 and the
Affymetrix NetAffx tool was used to map these probesets to their latest gene
mappings (641 genes). NCBI’s file for Mus musculus was used to find the
associated Mouse Genome Informatics (MGI) ids, yielding 636 associated MGI ids.
The HMD Human Phenotype.rpt file from the MGI Data and Statistical Reports site
served to map the 636 MGI ids to 586 unique human genes. Eight genes without
RNA-Seq information and 346 genes that were not differentially expressed were
also removed from the list. The remaining 232 genes were differentially expressed
(Po0.0001) in at least one of the three comparisons. An eIF2 network of 68 gene
symbols (Figure 4e, Supplementary Table 2), and a Nupr1 network of 205 gene
symbols (Figure 5d, Supplementary Table 4) were obtained from IPA and the
associated Entrez gene ids were queried using NCBI’s Homo sapiens gene
information. Of the 68 eIF2 network genes, 43 were differentially expressed
(Po0.0001) in at least one of the three comparisons. In the Nupr1 gene network,
three genes no longer had associated Entrez gene ids, and two were not
differentially expressed. The remaining 200 genes were differentially expressed
(Po0.0001) in at least one of the three comparisons. For all three networks, the
fold change values as compared with the untreated condition were plotted in
Figures 4b and e, and 5d, as a gradient from green (downregulated) to red
(upregulated) if Po0.001, and gray otherwise, using heatmap.2 in the R gplots
package.64 For GSEA of RNA-Seq data custom gene set was prepared with top 500
genes from eIF2- phosphorylation-dependent genes that were downloaded.9 Using
the GSEA pre-ranked tool, GSEA version 2.1.0 was run on ranked lists of genes,
sorted according to their modified log2 change differences, from the following
RNA-seq comparisons: ISRIB versus Control, Gem versus Control, Gem versus
Gem+ISRIB.
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Reverse transcription and real-time qPCR. RNA was isolated using
Qiagen-RNAeasy isolation kit (Qiagen), and quantified using Nanodrop (Wilmington,
DE, USA). RNA (2 μg) was used for cDNA preparation using RNA to cDNA reverse
transcription kit (Life Technology, Grand Island, NY, USA). 2x power SYBR Green
enzyme mix or Fast enzyme mix and Taqman primers (Applied Biosystem, Grand
Island, NY, USA) were used for quantitation of mRNA levels by real-time PCR. PCR
cycles and signal acquisition were performed using Vii-Applied Biosystem thermal
cycler (Applied Biosystem). Primers used for quantitation of mRNA levels ATF4:
F-ccaacaacagcaaggaggat, B-ggggcaaagagatcacaagt; CHOP: F-agaaccaggaaacgga
aacaga, B-tctccttcatgcgctgcttt; Gas5: F-cctcaaacttctgggctcaa, B-tcaggcagtctacaaag
accac; Asns: F-tacaaccacaaggcgctaca, B-aagggcctgactccataggt; Trib3: F-gtcttcgctg
accgtgaga, B-cagtcagcacgcaggactc; Slc7a11: F-gggcatctctctgaccatct, B-tcccaattcag
cataagacaaa; Sesn2: F-tccgccactcagagaagg, B-ggagggcgtacagcagag; Stc2: F-atatt
gtacagtcctttcgaccatt, B-cgtgcgtgtgtatgagtgtg; Sat1: F-gaggttccttgggtcatgg, B-gtggttcc
tcattcgtctcc; BEX2: F-gatgcagaaaatggtggtttg, B-cctctttggactccattactcc; Bcl2a1:
F-caggagaatggataaggcaaa, B-accagcataggtgtgtgattgt; ACTB: F-gagcgcggctacagctt,
B-tccttaatgtcacgcacgattt. Taqman primers used were as follows; GADD34:
Hs00169585_m1, ATF3: Hs00231069, Nupr1: Hs01044304, ACTB: Hs01060665_g1.
Polysome profile preparation. Polysome profile was prepared as
described previously.60 Briefly, PANC-1 cells were cultured as described above
and treated with 10 μM Gem or 0.5 μM ISRIB or in combination for 12 h. For the
experiment involving GADD34 expression, PANC-1 cells were transfected with
GADD34 expression plasmid, and 24 h post transfection the cells were incubated in
the presence or absence of 10 μM Gem for 12 h. Cycloheximide (10 μg/ml) was
added 10 min prior to cell harvesting. Cells were then washed with cold phosphate-
buffered saline (pH 7.4) solution containing 10 μg/ml cycloheximide and cell lysates
were prepared in a buffer solution containing 20 mM Tris–HCl (pH 7.5), 5 mM
MgCl2, 100 mM NaCl, and 0.4% Nonidet P-40 supplemented with 50 μg/ml
cycloheximide. Cell lysates were passed through a 23-gauge needle, incubated on
ice for 10 min, pre-cleared by a 10- min centrifugation (10 000 r.p.m., 4 °C), and
layered onto a 10–50% sucrose gradient solution containing 20 mM Tris–HCl
(pH 7.5), 5 mM MgCl2, 100 mM NaCl, and 10 μg/ml cycloheximide. Sucrose
gradients were then subjected to a 2- h centrifugation in a Beckman SW-41Ti rotor
(40 000 rpm, 4 °C). Gradients were fractionated using Biocomp Gradient Station
(Fredericton, NB, Canada) and absorbance of RNA at 254 nm was recorded using
an in-line UV monitor. Synthetic poly (A)+ luciferase RNA (Promega) was spiked
(10 ng/ml) into each collected fractions, and RNA was isolated from these fractions
using Trizol-LS reagent (Invitrogen). Single-stranded cDNA prepared using
Superscript III reverse transcriptase (Invitrogen). ATF4 mRNA transcript levels
were quantified using qRT-PCR, and data normalized with the spike-in luciferase
mRNA levels. Percent of total ATF4 mRNA in each fraction is represented in the
figure.
Orthotopic implantation of tumor cells and treatment
schedule. PANC-1 cells (0.5X106) expressing a Lenti-GFP plasmid were
suspended in 0.1 ml sterile PBS, and injected into the pancreas of 8-week-old nude
mice (Harlan, Indianapolis, IN, USA) as reported.65 Tumors were imaged 15 days
later, using the Vevo2100 high-resolution ultrasound (V-US) (Visual Sonics Inc.,
Toronto, Canada). Tumor volumes were calculated based on acquired 3-D
abdominal scans. Mice were divided into four groups (6 mice/group). On day 18
post-surgery, twice-weekly intraperitoneal drug administration was initiated. Group 1
received Gem (Biotang, Waltham, MA, USA), at a dose of 50 mg/kg body weight
dissolved in saline44 and DMSO containing PEG-400 (Sigma). Group 2 received
2.5 mg/kg body weight ISRIB (Xcessbio, San Diego, CA, USA) dissolved in DMSO
containing PEG-400 and saline.22 Group 3 received both Gem and ISRIB, whereas
Group 4 received saline and DMSO containing PEG-400. Tumor volumes were
determined by V-US at 8 weeks post-surgery. Mice were then killed and tumor
tissues were collected for analysis.
Immunohistochemistry. Orthotopic tumors were fixed in 10% formalin and
embedded in paraffin. H&E staining and immunohistochemistry were performed
using 5 μm-thick sections,65 anti-phospho-histone H3 (Novacastra Leica Micro-
systems, Buffalo Grove, IL, USA) and anti-cleaved PARP (Asp175; Cell Signaling
Technology, Danvers, MA, USA) antibodies. Sections were incubated in HRP-
labeled secondary antibody and staining was detected by DAB (Dako, Carpinteria,
CA, USA). Images were taken using an Olympus BX60 microscope (Olympus,
Center Valley, PA, USA) equipped with a QImaging EXI Blue camera and ImagePro
software (Media Cybernetics, Atlanta, GA, USA).
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